NCT07133802View on ClinicalTrials.gov

Clinical Trial to Evaluate the Protective Efficacy and Safety of a Nasal Spray Live Attenuated Influenza Vaccine (LAIV) in Adults Aged 18-59 Years Post-Vaccination

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

6,680

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

March 31, 2026

Study Completion Date

July 31, 2026

Conditions
Prevention of Influenza
Interventions
BIOLOGICAL

Placebo Group

Each human dose: 0.2 mL

BIOLOGICAL

Test Group

Each human dose is 0.2 mL

Sponsors
All Listed Sponsors
collaborator

Hubei Provincial Center for Disease Control and Prevention

OTHER

collaborator

Center for Disease Control and Prevention, Fujian

OTHER

collaborator

Zhejiang Provincial Center for Disease Control and Prevention

OTHER_GOV

lead

Changchun BCHT Biotechnology Co.

INDUSTRY

NCT07133802 - Clinical Trial to Evaluate the Protective Efficacy and Safety of a Nasal Spray Live Attenuated Influenza Vaccine (LAIV) in Adults Aged 18-59 Years Post-Vaccination | Biotech Hunter | Biotech Hunter